Dihydrogen hexahydroxyplatinate

Skin sensitisation

Administrative data

Endpoint:

skin sensitisation: in vivo (LLNA)

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Although the study is not a conventional guideline study, it is well-conducted and scientifically acceptable.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2011

Report date:

2011

Materials and methods

Principles of method if other than guideline:

The primary aim of the study was to evaluate the allergenic potential of the test substance and to determine its ability to cause allergic sensitization of the respiratory tract. Following analysis of lymphocyte proliferation using a standard local lymph node assay (LLNA) protocol cytokine fingerprinting was undertaken to explore respiratory sensitizing potential. Repeated topical exposure of BALB/c strain mice to chemical respiratory allergens, or contact allergens, has been shown to provoke characteristic cytokine secretion profiles consistent with the divergent activation of discreet T cell subpopulations. Cytokine profiles were compared with the recognised respiratory sensitizers Trimellitic anhydride (TMA) and Ammonium hexachloroplatinate (AHCP), as well as the known contact sensitizer 2,4-Dinitrochlorobenzene (DNCB) and the non-sensitizer Tetraammine platinum dichloride (TPC).

GLP compliance:

no

Remarks:

Non-standard guideline study conducted at academic institution

Type of study:

mouse local lymph node assay (LLNA)

Test material

Test material information

Constituent 1

Reference substance name:

Hexahydroxyplatinic acid

IUPAC Name:

Hexahydroxyplatinic acid

Constituent 2

Reference substance name:

Diaquatetrahydroxyplatinum

EC Number:

257-921-8

EC Name:

Diaquatetrahydroxyplatinum

Cas Number:

52438-26-3

IUPAC Name:

52438-26-3

Test material form:

solid - liquid: suspension

Details on test material:

- Name of test material (as cited in study report): Hexahydroxyplatinic acid (HHPA)
- Analytical purity: records of test compound characterisation, including purity, were held by the sponsor
- Other: All test preparations were fine suspensions of HHPA in DMF after sonification for 15 mins

In vivo test system

Test animals

Species:

mouse

Strain:

Balb/c

Sex:

not specified

Study design: in vivo (LLNA)

Vehicle:

dimethylformamide

Concentration:

40% and 80% in LLNA; 80% for cytokine fingerprinting

No. of animals per dose:

4/group in LLNA; 3/group for cytokine fingerprinting

Details on study design:

Using a standard LLNA protocol, mice (4/group) received 25 ul of chemical [80% or 40% HHPA in DMF, or DMF alone] on the dorsum of both ears on days 0, 1 and 2. Five days after the initiation of treatment, draining lymph nodes were isolated, pooled on a treatment group basis and a single cell suspension prepared. Total cellularity per lymph node was recorded. Cells (in quintuplicate) were cultured at 107 cells/ml for 24 hr in the presence of radiolabelled thymidine (2 uCi). Culture was terminated by automated cell harvesting and thymidine incorporation measured by beta-scintillation counting.

Results and discussion

Positive control results:

Details on positive and negative control results for the cytokine fingerprinting assay are presented below under Any other information on results incl tables

In vivo (LLNA)

Results

Results 1

Parameter:

SI

Remarks on result:

other: See results, below

Results 2

Parameter:

other: disintegrations per minute (DPM)

Remarks on result:

other: Full details on results are presented below under Any other information on results incl. tables

Any other information on results incl. tables

HHPA displayed some activity in the modified LLNA, with 80% HHPA/DMF achieving a combined stimulation index (SI) of 5.7. Full results are given below:

Treatment	Cellularity (cells/lymph node x 10^6)	Thymidine incorporation (dpm)	Combined Stimulation Index (SI)
80% HHPA/DMF	5.5	8570	5.7
40% HHPA/DMF	7.3	6285	5.4
DMF	4.25	1953	1

In the 13 -day cytokine fingerprinting assay, total cellularity per lymph node was recorded as a measure of immune activation. Topical exposure to the positive control substances TMA and DNCB induced marked increases in lymph node cellularity. AHCP induced a more modest increase in lymph node cellularity, whereas TPC and HHPA were without marked effects on lymph node cell (LNC) numbers. Full results are given below:

Treatment	Cellularity (cells/lymph node x 10^6)
10% TMA/AOO	13.5
1% DNCB/AOO	14.3
5% AHCP/DMF	11.5
5% TPC/DMF	4
80% HHPA/DMF	4

Type 2 cytokine IL-4 results are presented below. LNCs isolated from the known skin sensitizer DNCB treated mice expressed very low levels of IL-4, whilst treatment with the respiratory sensitizer TMA resulted in relatively vigorous IL-4 expression. Exposure to AHCP (also known to be a respiratory sensitizer) also induced the production of IL-4, albeit at lower levels than that provoked by TMA. Treatment with 80% HHPA (or 5% of the non-sensitizer TPC), however, stimulated very low levels of IL-4 production:

Treatment	IL-4 (pg/ml)
10% TMA/AOO	668
1% DNCB/AOO	73
5% AHCP/DMF	213
5% TPC/DMF	11
80% HHPA/DMF	20

In the analysis of additional type 2 cytokines (IL-5, IL-10, IL-13) and type 1 cytokines (IL-12, IFN-gamma), LNCs derived from TPC-treated animals expressed relatively low levels of all cytokines with the exception of (type 1) IL-12. DNCB exhibited a selective type 1 cytokine profile with relatively vigorous IFN-gamma production and IL-12 expression, but relatively low levels of type 2 cytokines IL-5, IL-10 and IL-13. TMA-activated LNCs expressed a type 2 cytokine profile with relatively high levels of IL-5, IL-10 and IL-13, but low levels of the type 1 cytokines. A similar type 2 pattern of cytokine expression was recorded following topical exposure to AHCP. For HHPA-activated LNCs, levels of type 2 cytokines were below the limit of detection and the cytokine profile was similar to the non-sensitizing TPC.

Type 2 cytokines	IL-5 (pg/ml)			IL-10 (pg/ml)			IL-13 (pg/ml)
Treatment	96 hr	120 hr	144 hr	96 hr	120 hr	144 hr	96 hr	120 hr	144 hr
10% TMA/AOO	289	335	576	594	822	1019	872	1043	1423
1% DNCB/AOO	209	165	65	47	55	22	164	136	27
5% AHCP/DMF	98	175	98	101	129	187	75	142	99
5% TPC/DMF	ND*	<10	<10	ND*	<10	<10	ND*	<10	<10
80% HHPA/DMF	ND*	<10	<10	ND*	<10	<10	ND*	<10	<10

*not done - insufficient cells

Type 1 cytokines	IL-12 (pg/ml)			IFN-gamma (pg/ml)
Treatment	96 hr	120 hr	144 hr	96 hr	120 hr	144 hr
10% TMA/AOO	108	110	104	389	321	398
1% DNCB/AOO	187	201	209	1225	1241	1130
5% AHCP/DMF	97	86	86	93	126	116
5% TPC/DMF	ND*	154	152	ND*	16	<10
80% HHPA/DMF	ND*	132	138	ND*	<10	<10

*not done - insufficient cells

Total serum IgE concentrations are presented below:

	IgE concentration (ng/ml)
Treatment	No 1	No 2	No 3
10% TMA/AOO	1864	1230	966
5% AHCP/DMF	654	1354	2937
5% TPC/DMF	49	36	14
80% HHPA/DMF	59	47	ND*

*not done - mouse terminated early due to lymphoproliferative disorder, not compound related.

TMA and AHCP resulted in marked increases in total serum IgE concentration compared with the negative control platinum TPC. There was no marked elevation in total serum IgE following topical exposure to HHPA.

Applicant's summary and conclusion

Interpretation of results:

not sensitising

Remarks:

Migrated information Criteria used for interpretation of results: expert judgment

Conclusions:

Hexahydroxyplatinic acid (HHPA) at high concentrations demonstrated a mild sensitisation response using a conventional Local Lymph Node Assay (LLNA) (40% and 80% HHPA in DMF gave a Stimulation Index (SI) of 5.4 and 5.7, respectively). However, the more sophisticated detailed cytokine fingerprinting assay indicated that it was not a significant skin or respiratory sensitiser, demonstrating a cytokine profile similar to that of the recognised non-sensitiser tetraammineplatinum dichloride.

Executive summary:

Hexahydroxyplatinic acid (HHPA) was subjected to a modified LLNA, combined with a detailed cytokine fingerprinting assay, to evaluate its allergenic potential, particularly with regard to its ability to cause sensitisation of the respiratory tract.

 

Mice (4/group) received a 25 μL application of HHPA (concentrations of 40% or 80% HHPA in DMF, or DMF alone) on the dorsum of both ears on three consecutive days. Five days after the initiation of treatment, cell proliferation in the local lymph nodes was measured by incorporation of radiolabelled thymidine.

 

Subsequently, a standard 13-day cytokine fingerprinting assay was undertaken, involving mice (3/group) exposed to 80% HHPA in DMF. Additional groups of mice were treated with ammonium hexachloroplatinate (AHCP) (a respiratory sensitising platinum salt; positive control), tetraammineplatinum dichloride (TPC) (a non-sensitising platinum salt; negative control), as well as the reference respiratory allergen trimellitic anhydride (TMA) or the reference contact allergen 2,4 -dinitrochlorobenzene (DNCB). Animals received 50 μL of test chemical on both shaved flanks on day 0 and day 5, followed by a further dose of 25 μL of chemical on the dorsum of both ears on days 10, 11 and 12.

 

In the LLNA, the observed Stimulation Index (SI) values were 5.4 and 5.7 at 40 and 80%, respectively, demonstrating a mild sensitisation response. However, the more sophisticated detailed cytokine fingerprinting assay indicated that the test material was not a significant skin or respiratory sensitiser. Type 1 and type 2 cytokine profiles were compared with those of the known respiratory sensitisers TMA and AHCP, the contact sensitizer DNCB, and the known non-sensitiser TPC. HHPA failed to stimulate vigorous type 2 cytokine production, indicating a lack of respiratory sensitising potential, and demonstrated a cytokine profile similar to that of the non-sensitiser TPC. Type 1 cytokine IFN-gamma was below the limit of detection, and IL-12 was not elevated above normal background values, based on historical vehicle controls.

 

Overall, the results suggest that HHPA is not a significant skin or respiratory tract sensitiser. It is recommended that a lack of skin sensitising potential be confirmed using a standard in vivo assay for skin sensitisation using guinea-pigs.